Raka Saurabh, Belemkar Sateesh, Bhattacharya Sankha
Department of Pharmaceutics, School of Pharmacy and Technology Management, SVKM'S NMIMS Deemed-to-be University, Shirpur, Maharashtra, 425405, India.
Department of Pharmacology, Shobhaben Pratapbhai Patel School of Pharmacy and Technology Management SVKMs NMIMS Deemed-to-be University, V L Mehta Road, Vile Parle (West), Mumbai, 400 056, Maharashtra, India.
Curr Med Chem. 2024 Jun 24. doi: 10.2174/0109298673309011240606095639.
Theranostics, a method that combines targeted therapy and diagnostic imaging, has emerged as a viable route for enhancing cancer treatment, and hybrid nanoparticles (HNPs) are at the forefront of this field. Metallic, polymeric, lipid-based, and silica- based HNPs are studied for targeting and biocompatibility. Using HNPs, chemotherapeutic drugs, small interfering RNA, and therapeutic genes can be given precisely and controlled. This enhances therapeutic efficacy and reduces adverse effects. With fluorescence dyes, MRI contrast agents, and PET tracers, real-time therapy response monitoring is conceivable. A nano platform with therapeutic and diagnostic capabilities holds great promise for personalized medicine and precision oncology. The present study discusses HNPs' biocompatibility, stability, immunogenicity, and long-term biosafety, which are crucial to the clinical translation of cancer theranostics. Further, in this in- -depth investigation, we investigated the design, synthesis, and multifunctional activities of HNPs for use in cancer theranostics.
治疗诊断学是一种将靶向治疗与诊断成像相结合的方法，已成为增强癌症治疗效果的可行途径，而杂化纳米粒子（HNPs）处于该领域的前沿。人们对基于金属、聚合物、脂质和二氧化硅的杂化纳米粒子的靶向性和生物相容性进行了研究。使用杂化纳米粒子，可以精确且可控地递送化疗药物、小干扰RNA和治疗性基因。这提高了治疗效果并减少了不良反应。借助荧光染料、磁共振成像（MRI）造影剂和正电子发射断层扫描（PET）示踪剂，可以实现对治疗反应的实时监测。一个具有治疗和诊断能力的纳米平台在个性化医疗和精准肿瘤学方面具有巨大潜力。本研究讨论了杂化纳米粒子的生物相容性、稳定性、免疫原性和长期生物安全性，这些对于癌症治疗诊断学的临床转化至关重要。此外，在这项深入研究中，我们研究了用于癌症治疗诊断学的杂化纳米粒子的设计、合成和多功能活性。
